Getinge AB Stock

Getinge AB (publ) operates as a global provider of products and solutions for operating rooms, intensive care units, and sterilization departments serving 40 countries and with proprietary production in nine countries.

The company’s sales take place through proprietary companies and distributors in 132 countries. Approximately 70% of sales are conducted through the company’s sales companies and the remaining 30% are sold by agents and distributors in markets where the company often lacks proprietary representation.

The company’s production is conducted at a total of 20 facilities in France, China, the Netherlands, Poland, the U.K., Sweden, Türkiye, Germany, and the U.S.

Segments

The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments.

Acute Care Therapies segment

This segment offers products and solutions for life support and therapies in acute health conditions. The offering includes solutions for cardiac, pulmonary, and vascular therapies; and a broad selection of products and therapies for intensive care.

The company develops advanced clinical solutions that can contribute to improving therapy results, achieving more rapid recovery and enhancing quality of life for patients in intensive care and surgery.

Several new products and updates were introduced during 2021. The HL 40 heart-lung machine, which was launched commercially in several countries in April, is designed to increase safety and ensure maximum uptime in cardiac surgery. In the second quarter, the company also received the U.S. Food and Drug Administration (FDA) 510(k) clearance for three products in the U.S., expanding the Servo ventilator platform offering. Rotaflow II, a new life support product, was launched in certain markets in the third quarter. The technology offers up to 14 days of extracorporeal membrane oxygenation (ECMO) therapy in a compact manner, which gives health care personnel the flexibility they need to provide high quality patient care.

Talis Clinical LLC, a U.S.-based leading innovator of High Acuity cloud-based software solutions, was acquired in December. Talis Clinical LLC’s offer is designed to support and document care throughout the operative care process, but also through labor and delivery episodes and critical care support, including ECMO therapy. The company also owns a minor acquisition of Irasun GmbH, which is based in Munich. The acquisition has enabled the company to broaden its portfolio to include innovative solutions in ECMO therapy and cardiac surgery.

Products

Intensive Care: The company offers life support therapies for intensive care, in the form of ventilators, hemodynamic monitoring and ECMO. The main competitors are Dräger, Hamilton, Medtronic, Edwards, and Lifesciences.

Cardiovascular Surgery: The company offers products for advanced cardiac surgery, such as heart-lung machines, heater-cooler units, beating heart surgery, endoscopic vessel harvesting, left atrial appendage closure devices, anesthesia systems, aortic and peripheral vascular grafts and thoracic drainage systems. The main competitors are LivaNova, Terumo, GE Healthcare Life Sciences, Dräger, WL Gore, and Medtronic.

Cardiovascular Interventions: The company offers products to facilitate cardiovascular procedures, such as products for cardiac assist and peripheral vascular stents. The main competitors are WL Gore, Medtronic, Boston Scientific, Abbott Vascular, Cook, and BD.

Life Science segment

Life Science segment offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in biopharmaceutical production, biomedical research, medical device manufacturing, and laboratory applications.

This segment delivers effective solutions that help customers optimize their processes and thereby meet regulatory requirements. The offering includes ports, containers and single-use bags for sterile transfer of components, tools and fluids, in and out of aseptic filling lines; bioreactor systems for research and production of vaccines, antibodies, enzymes and bio-plastics for industrial biotechnology; sterilizers for the sterilization of pharmaceuticals and medical devices; washer-disinfectors for cleaning of technical production equipment; and isolators for the protection of operators and quality assurance of aseptic processes.

Customers include world-leading manufacturers of pharmaceuticals and medical devices. These customers need effective research and production processes free from contamination.

The company intends to further develop the range of single-use bioreactors used for research and production of biopharmaceuticals. In addition, the company intends to further strengthen its leading position in sterile transfer.

Products

Pharma Production: The company offers sterile/aseptic transfer solutions, GMP sterilizers, GMP washers, bioreactors, logistic automation, and isolators. The main competitors are Fedegari, Steris, Steelco, Sartorius, GE, and Thermo Fisher.

Medical Research: The company offers lab washers and sterilizers, cage washers and sterilizers, bioreactors, and logistic automation. The main competitors are Steris, Steelco/Miele, IWT, Sartorius, and Eppendorf.

Surgical Workflows segment

Surgical Workflows segment is a supplier of products and solutions to serve as an end-to-end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms. The offering includes products for sterile reprocessing; operating room equipment; IT systems for efficient workflows; and services.

Surgical Workflows segment offers products and services for efficient disinfection and sterilization of instruments used in operations, operating tables and other high-quality hardware for operating rooms and advanced IT systems for efficient and secure hospital workflows.

In addition to proprietary product development, Surgical Workflows engages in several strategic collaborations, for example with world-leading manufacturers of medical imaging technologies for hybrid ORs.

One of the launches during 2021 were Torin Artificial Intelligence (AI), which is designed to improve efficiency in managing schedules for surgical procedures; and the VisioNIR feature in Maquet Volista StandOP – an innovative solution, which makes it possible to keep the surgical light on when performing open surgeries using NIR fluorescence imaging systems. In the third quarter, the company acquired technology related to biological indicators from Verrix, a U.S. start-up company.

Offering

Sterile Supply Department: The company offers complete systems and automation for the sterilization of instruments used in surgery, including sterilizers, low temperature sterilizers and disinfectors, as well as consumables and service. The main competitors are Steris, Steelco, Shinva, Belimed, and ASP.

Operating Room Equipment: The company offers complete operating room solutions, including high-end hybrid operating rooms in combination with imaging partners, advanced operating tables, lights and ceiling supply units, and modular room systems, as well as consulting on layouts, workflows and technical service. The main competitors are HillRom/Trumpf, Steris, Stryker, Mindray, and Dräger.

Integrated Solutions for Operating Rooms: The company offers IT systems to enhance efficiency and safety in the flow of patients, employees and sterile equipment to and from the operating room. The main competitors are Censis and Teletracking.

Strategy

The company’s strategies are to drive productivity and efficiency enhancement; secure leadership by strengthening the offering; capitalize on having one truly global brand; capture global growth; work continuously on securing a quality mindset throughout the organization and continuously improves its products, services and processes; and contribute to sustainable health care through increased environmental and social responsibility that has a positive impact on society.

Research and Development

The company’s research and development costs amounted to SEK (Swedish krona) 1,197 M (millions of kronor) in 2021.

History

Getinge AB (publ) was founded in 1904.